Evaluation of the effect of MTNR1B rs10830963 gene variant on the therapeutic efficacy of nateglinide in treating type 2 diabetes among Chinese Han patients

Table 3 Clinical characteristics of T2DM patients before and after nateglinide treatment (n = 60)

Parameters	Before treatment n = 60	After treatment n = 60	P values
BMI (kg/m²)	25.41 ± 3.54	25.33 ± 3.11	0.896
WHR	0.92 ± 0.06	0.91 ± 0.06	0.363
FPG (mmol/L)	10.41 ± 1.23	7.25 ± 1.21	0.000*
PPG (mmol/L)	14.56 ± 2.76	9.38 ± 2.61	0.000*
FINS (mU/L)	7.56 ± 4.39	9.51 ± 3.46	0.008*
PINS (mU/L)	30.31 ± 17.10	47.21 ± 15.16	0.000*
HOMA-IR	3.57 ± 1.30	2.72 ± 1.41	0.001*
HOMA-β	25.73 ± 14.5	60.32 ± 21.15	0.000*
HbA1c (%)	9.31 ± 1.87	7.89 ± 0.81	0.000*
TG (mmol/L)	2.25 ± 1.38	1.86 ± 1.23	0.105
TC (mmol/L)	5.21 ± 1.29	4.31 ± 1.09	0.000*
HDL-c (mmol/L)	1.38 ± 0.75	1.45 ± 0.59	0.571
LDL-c (mmol/L)	3.85 ± 1.78	3.42 ± 1.07	0.111

BMI body mass index, WHR waist to hip ratio, FPG fasting plasma glucose, PPG postprandial plasma glucose, FINS fasting serum insulin, PINS postprandial serum insulin, HOMA-IR homeostasis model assessment for insulin resistance, HOMA-β Homeostasis model assessment for islet β cell function, HbA1c hemoglobin A1c, TG triglyceride, TC total cholesterol, HDL-c high-density lipoprotein-cholesterol, LDL-c low-density lipoprotein-cholesterol
Data are expressed as (mean ± SD). P values are determined by the paired Student’s t test. *P < 0.05

ISSN: 1755-8794